Recombinant human erythropoietin: 10 years of clinical experience

Nephrology Dialysis Transplantation

Volumn 13, Issue SUPPL. 2, 1998, Pages 3-8

  Winearls, C G ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anaemia; Chronic renal failure; Erythropoietin; Iron

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BONE MARROW; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON STORAGE; IRON THERAPY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031958358     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.suppl_2.3     Document Type: Conference Paper

References (35)

1. Hegstrom RM, Murray JS, Pendras JP, Burnell JM, Scribner BH. Hemodialysis in the treatment of chronic uremia. American Society for Artificial Internal Organs 1961; 7: 136-152.
2. Erslev AJ. Erythropoietin: from physiology to clinical trials via molecular biology. In: Erslev A, Adamson J, Eschbach J, Winearls C, ed. Erythropoietin: molecular, cellular and clinical biology. The John Hopkins University Press, Baltimore and London: 1991: 3-18.
3. Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Scigalla P. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 1988; 66: 85-93.
4. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European Multicentre Study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979-987.
5. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989; 111: 992-1000.
6. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67.
7. Nijhof W, de Haan G, Pietens J, Dontje B. Mechanistic options of erythropoietin-stimulated erythropoiesis. Exp Hematol 1995; 23: 369-375.
8. Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, Royston JP. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of erythropoietin (r-HuEPO). An investigation of the pharmaco-kinetics of intravenous r-HuEPO and its effect on erythrokinetics. Q J Med 1989; 70: 113-137.
9. Reid CDL, Fiddler J, Winearls CG, Oliver DO, Cotes PM. The response of erythroid progenitors to administered recombinant human erythropoietin in haemodialysed renal failure patients. Blood 1987; 70 [Suppl]: 142a.
10. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with comorbid disease. Am J Nephrol 1992; 12: 303-310.
11. Hörl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. Acta Haematol 1992; 87 [Suppl I]: 16-19.
12. Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin Nephrol 1994; 41: 297-302.
13. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997; 8: 288-293.
14. Frenken LAM, van Lier HJJ, Gerlag PGG. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. Br Med J 1991; 303: 288.
15. Granolleras C, Leskopf W, Shaldon S. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomised double-blind cross-over study. Clin Nephrol 1991; 36: 294-298.
16. Veys N, Vanholder R, Lamiere N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance haemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992; 12: 68-72.
17. Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile. Nephrol Dial Transplant 1991; 12: 955-965.
18. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300: 573-578.
19. Auer J, Oliver DO, Winearls CG. The quality of life of dialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol Suppl 1990; 131: 61-65.
20. Macdougall IC, Eckardt K-U. Haematological disorders. In: Davison AM, Cameron JS, Ritz E, Kerr DNS, Grunfeld J, and Winearls CG, eds. Oxford textbook of clinical nephrology. Oxford University Press, Oxford: 1997: 7.115-7.134.
21. Bommer J, Samtleben W, Koch KM, Baldamus CA, Grützmacher P, Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol 1989; 76: 149-158.
22. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. New Engl J Med 1996; 334: 420-425.
23. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994; 307: 353-359.
24. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 1991; 6: 342-345.
25. Rao DS, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. New Engl J Med 1993; 328: 171-175.
26. Teruel JL, Marcen R, Villafruela JJ, Navarro-Antolin J, Ortuno J. Quantitative assessment of erythropoiesis after subtotal parathyroidectomy. Nephrol Dial Transplant 1997; 12: 367-368.
27. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia [letter; comment]. New Engl J Med 1996; 335: 523-524.
28. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178.
29. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-148.
30. Edmunds ME, Walls J, Tucker B et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4: 1065-1069.
31. Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 1992; 7: 811-816.
32. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New Engl J Med 1987; 316: 73-78.
33. Casati S, Passerini P, Campise MR et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020.
34. Movilli E, Cancarini GC, Mombelloni S. The role of hematocrit in efficiency of dialysis. Blood Purif 1990; 8: 183-189.
35. Sieff CA, Nathan DG. Haemopoietic stem cells. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine. Third edn. Oxford University Press, Oxford: 1996: (22.2.1): 3381-3390.